[
  {
    "date": "2023-12-30",
    "symbol": "ITOS",
    "period": "FY",
    "netincomeloss": -112642000,
    "documenttype": "10-K",
    "amendmentflag": "false",
    "documentperiodenddate": "2023-12-31",
    "documentfiscalyearfocus": 2023,
    "documentfiscalperiodfocus": "FY",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "tradingsymbol": "ITOS",
    "entityregistrantname": "iTeos Therapeutics, Inc.",
    "entitycentralindexkey": 1808865,
    "currentfiscalyearenddate": "--12-31",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityinteractivedatacurrent": "Yes",
    "entityfilercategory": "Accelerated Filer",
    "entitysmallbusiness": "false",
    "entityemerginggrowthcompany": "true",
    "entityextransitionperiod": "false",
    "entityincorporationstatecountrycode": "DE",
    "entityshellcompany": "false",
    "entityfilenumber": "001-39401",
    "entitytaxidentificationnumber": "84-3365066",
    "entityaddressaddressline1": "321 Arsenal St",
    "entityaddresscityortown": "Watertown",
    "entityaddressstateorprovince": "MA",
    "entityaddresspostalzipcode": 2472,
    "cityareacode": 339,
    "localphonenumber": "217 0162",
    "security12btitle": "Common stock, $0.001 par value per share",
    "securityexchangename": "NASDAQ",
    "icfrauditorattestationflag": "false",
    "auditorname": "Deloitte Bedrijfsrevisoren/Réviseurs d’Entreprises BV/SRL",
    "auditorlocation": "Zaventem, Belgium",
    "auditorfirmid": 1133,
    "documentfinstmterrorcorrectionflag": "false",
    "cashandcashequivalentsatcarryingvalue": 251177000,
    "shortterminvestments": 280739000,
    "researchanddevelopmenttaxcreditreceivablecurrent": 135000,
    "incometaxreceivable": 6365000,
    "prepaidexpenseandotherassetscurrent": 12236000,
    "assetscurrent": 550652000,
    "propertyplantandequipmentnet": 4696000,
    "longterminvestments": 100539000,
    "researchanddevelopmenttaxcreditreceivablenoncurrent": 4508000,
    "restrictedcashnoncurrent": 274000,
    "operatingleaserightofuseasset": 6036000,
    "otherassetsnoncurrent": 883000,
    "assets": 667588000,
    "accountspayablecurrent": 11293000,
    "accountspayableandotheraccruedliabilitiescurrent": 7058000,
    "employeerelatedliabilitiescurrent": 8562000,
    "payableinvestmentpurchase": 9787000,
    "deferredincomecurrent": 2063000,
    "operatingleaseliabilitycurrent": 1251000,
    "liabilitiescurrent": 40014000,
    "grantsrepayable": 6609000,
    "operatingleaseliabilitynoncurrent": 4807000,
    "unrecognizedtaxbenefits": 40930000,
    "liabilities": 92360000,
    "commonstockvalue": 36000,
    "additionalpaidincapital": 463799000,
    "accumulatedothercomprehensiveincomelossnetoftax": -13240000,
    "retainedearningsaccumulateddeficit": 124633000,
    "stockholdersequity": 575228000,
    "liabilitiesandstockholdersequity": 667588000,
    "debtsecuritiesavailableforsaleamortizedcostcurrent": 281035000,
    "debtsecuritiesavailableforsaleamortizedcostnoncurrent": 100208000,
    "preferredstockparorstatedvaluepershare": 0.001,
    "preferredstocksharesauthorized": 10000000,
    "commonstockparorstatedvaluepershare": 0.001,
    "commonstocksharesauthorized": 150000000,
    "commonstocksharesissued": 35838080,
    "commonstocksharesoutstanding": 35838080,
    "revenuefromcontractwithcustomerincludingassessedtax": 12595000,
    "revenues": 12595000,
    "researchanddevelopmentexpense": 113300000,
    "generalandadministrativeexpense": 50396000,
    "operatingexpenses": 163696000,
    "operatingincomeloss": -151101000,
    "grantincome": 2687000,
    "researchanddevelopmenttaxcredits": 3527000,
    "interestincomeother": 31774000,
    "othernonoperatingincomeexpense": 4083000,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": -109030000,
    "incometaxexpensebenefit": 3612000,
    "netincomelossavailabletocommonstockholdersbasic": -112642000,
    "earningspersharebasic": -3.15,
    "earningspersharediluted": -3.15,
    "weightedaveragenumberofsharesoutstandingbasic": 35763520,
    "weightedaveragenumberofdilutedsharesoutstanding": 35763520,
    "othercomprehensiveincomelossforeigncurrencytransactionandtranslationadjustmentnetoftax": -3631000,
    "othercomprehensiveincomelossavailableforsalesecuritiesadjustmentnetoftax": 35000,
    "comprehensiveincomenetoftax": -116238000,
    "sharesoutstanding": 35838080,
    "adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalue": 27021000,
    "stockissuedduringperiodvalueemployeestockpurchaseplanandreleaseofrestrictedstockunits1": 1113000,
    "stockissuedduringperiodsharesemployeestockpurchaseplanandreleaseofrestrictedstockunits": 226861,
    "stockissuedduringperiodsharesstockoptionsexercised": 184937,
    "othercomprehensiveincomeforeigncurrencytransactionandtranslationgainlossarisingduringperiodnetoftax": -3631000,
    "debtsecuritiesavailableforsaleunrealizedgainloss": 35000,
    "profitloss": -112642000,
    "depreciationandamortization": 898000,
    "sharebasedcompensation": 27021000,
    "netaccretionofavailableforsaledebtsecurities": -10234000,
    "increasedecreaseingrantsreceivable": 1015000,
    "increasedecreaseinresearchanddevelopmenttaxcreditreceivable": 3400000,
    "refundableincometaxes": -4934000,
    "increasedecreaseinprepaiddeferredexpenseandotherassets": -184000,
    "increasedecreaseinaccountspayable": 3036000,
    "increasedecreaseinaccruedliabilities": 5342000,
    "increasedecreaseincontractwithcustomerliability": 823000,
    "increasedecreaseindeferredrevenue": -12595000,
    "increasedecreaseinunrecognizedtaxbenefits": -1730000,
    "netcashprovidedbyusedinoperatingactivities": -103756000,
    "paymentstoacquireinvestments": 290541000,
    "proceedsfromsaleandmaturityofmarketablesecurities": 366264000,
    "paymentstoacquirepropertyplantandequipment": 2966000,
    "paymentstoacquireotherproductiveassets": 99000,
    "netcashprovidedbyusedininvestingactivities": 72658000,
    "proceedsfromissuanceofcommonstock": 1113000,
    "netcashprovidedbyusedinfinancingactivities": 1113000,
    "effectofexchangerateoncashcashequivalentsrestrictedcashandrestrictedcashequivalentsincludingdisposalgroupanddiscontinuedoperations": -3602000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincludingexchangerateeffect": -33587000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalents": 251451000,
    "capitalexpenditureincludedinaccountspayable": 354000,
    "rightofuseassetobtainedinexchangeforoperatingleaseliability": 2155000,
    "othercomprehensiveincomelossavailableforsalesecuritiesadjustmentbeforetax": 35000,
    "incometaxespaidnet": 6816000,
    "concentrationriskpercentage1": 0.69,
    "researchanddevelopmenttaxcreditspercentage": 0.205,
    "numberofoperatingsegments": 1,
    "propertyplantandequipmentusefullife": "P3Y",
    "propertyplantandequipmentusefullifedescriptionoftermextensibleenumeration": "http://fasb.org/us-gaap/2023#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember",
    "cashequivalentsatcarryingvalue": 228406000,
    "assetsfairvaluedisclosure": 193076000,
    "interestincomedebtsecuritiesavailableforsaleoperating": 21500000,
    "proceedsfromsaleofavailableforsalesecuritiesdebt": 10200000,
    "availableforsaledebtsecuritiesamortizedcostbasis": 193231000,
    "availableforsaledebtsecuritiesaccumulatedgrossunrealizedgainbeforetax": 90000,
    "availableforsaledebtsecuritiesaccumulatedgrossunrealizedlossbeforetax": 245000,
    "availableforsalesecuritiesdebtsecurities": 193076000,
    "availableforsalesecuritiesdebtmaturitieswithinoneyearamortizedcost": 281035000,
    "availableforsalesecuritiesdebtmaturitiesafteronethroughfiveyearsamortizedcost": 100208000,
    "availableforsalesecuritiesdebtmaturitieswithinoneyearfairvalue": 280739000,
    "availableforsalesecuritiesdebtmaturitiesafteronethroughfiveyearsfairvalue": 100539000,
    "propertyplantandequipmentgross": 3434000,
    "accumulateddepreciationdepletionandamortizationpropertyplantandequipment": 4382000,
    "accruedclinicaltrialcostscurrent": 6956000,
    "accruedprofessionalfeesandotheraccruedliabilitiescurrent": 102000,
    "accruedliabilitiescurrent": 7058000,
    "upfrontpaymentreceived": 625000000,
    "maximumoptionfeesreceivablebasedonachievementofresearchmilestones": 45800000,
    "maximumadditionalreceivablebasedonachievementofresearchmilestones": 14500000,
    "optionfees": 1000000,
    "additionalmilestonepaymentaccrued": 2000000,
    "costsharecostsincurredforlicenseagreement": 39600000,
    "capitalizedcontractcostnet": 6800000,
    "costsrelatedtoglobaldevelopmentplan": 0.6,
    "operatingcostsandexpenses": 900000000,
    "percentageofgrantreimburseofactualqualifyingexpenditures": 0.55,
    "researchanddevelopmentarrangementwithfederalgovernmentcostsincurrednet": 2700000,
    "royaltyaccrualsduetorevenuerecognized": 800000,
    "grantsreceivable": 20900000,
    "percentageofrepaymentamountreceivedundergrant": 0.3,
    "termofrepaymentamountreceivedundergrant": 2023,
    "percentageofroyaltyonrevenue": 0.0033,
    "deferredincomenoncurrent": 5496000,
    "proceedsreceivedfromgrants": 4419000,
    "capitalunitsauthorized": 160000000,
    "commonstockvotingrights": "Each share of common stock entitles the holders to one vote on all matters submitted to a vote of the Company’s stockholders.",
    "sharebasedcompensationarrangementbysharebasedpaymentawardexpirationperiod": "P7Y",
    "sharebasedcompensationarrangementbysharebasedpaymentawardawardvestingrightspercentage": 0.25,
    "sharebasedcompensationarrangementbysharebasedpaymentawardawardvestingperiod1": "P36M",
    "sharebasedcompensationarrangementbysharebasedpaymentawardnumberofoptionsauthorized": 3464316,
    "commonstockcapitalsharesreservedforfutureissuance": 9115915,
    "stockissuedduringperiodsharesemployeestockpurchaseplans": 37549,
    "allocatedsharebasedcompensationexpense": 6619000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodweightedaveragegrantdatefairvalue": 11.6,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisesinperiodtotalintrinsicvalue": 2200000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedinperiodfairvalue1": 28100000,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedsharebasedawardsotherthanoptions": 46700000,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedperiodforrecognition1": "P2Y8M12D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": "P5Y6M",
    "sharebasedcompensationarrangementbysharebasedpaymentawardpurchasepriceofcommonstockpercent": 0.85,
    "estimatedweightedaveragefairvalueofissuedshares": 7.19,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedpercentage": 1,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedinperiod": 4375,
    "sharebasedcompensationarrangementbysharebasedpaymentawardpershareweightedaveragepriceofsharespurchased": 10.91,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsoutstandingweightedaverageremainingcontractualterms": "P3Y",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 8270220,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": 2324597,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresinperiod": 271427,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingnumber": 8270220,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisablenumber": 4746431,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 17.73,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice": 15.25,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodweightedaverageexerciseprice": 3.92,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsforfeituresinperiodweightedaverageexerciseprice": 24.14,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingweightedaverageexerciseprice": 17.73,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageexerciseprice": 16.01,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": "P6Y6M",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingweightedaverageremainingcontractualterm1": "P6Y6M",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageremainingcontractualterm1": "P5Y3M18D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingintrinsicvalue": 16299000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingaggregateintrinsicvalue": 16299000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableintrinsicvalue1": 14859000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrateminimum": 0.0346,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestratemaximum": 0.0473,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrateminimum": 0.82,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityratemaximum": 0.96,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionscommonstock": 9.76,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsnonvestednumber": 517625,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiod": 512000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsnonvestedweightedaveragegrantdatefairvalue": 11.81,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaveragegrantdatefairvalue": 11.55,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedinperiodweightedaveragegrantdatefairvalue": 35.86,
    "incomelossfromcontinuingoperationsbeforeincometaxesdomestic": -70172000,
    "incomelossfromcontinuingoperationsbeforeincometaxesforeign": -38858000,
    "effectiveincometaxratecontinuingoperations": -0.033,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.21,
    "valuationallowancedeferredtaxassetchangeinamount": 29000000,
    "deferredtaxassetsvaluationallowance": 74398000,
    "deferredtaxassetsoperatinglosscarryforwardsstateandlocal": 8500000,
    "operatinglosscarryforwardsexpirationyear": 2043,
    "unrecognizedtaxbenefitsinterestonincometaxesaccrued": 1700000,
    "effectiveincometaxratereconciliationstateincometaxespercent": 0.049,
    "effectiveincometaxratereconciliationforeignincometaxratedifferential": 0.012,
    "effectiveincometaxratereconciliationrelatingtonontaxableincomeandnondeductibleexpense": -0.001,
    "effectiveincometaxratereconciliationgiltipercent": -0.001,
    "effectiveincometaxrateunrecognizedtaxbenefits": -0.016,
    "effectiveincometaxratereconciliationotherreconcilingitemspercent": -0.012,
    "effectiveincometaxratereconciliationchangeinvaluationallowancepercent": -0.256,
    "currentfederalstateandlocaltaxexpensebenefit": 3612000,
    "deferredtaxassetsoperatinglosscarryforwards": 21796000,
    "deferredtaxassetstaxcreditcarryforwardsforeign": 17980000,
    "section174capitalizedresearchanddevelopmentexpenses": 27913000,
    "deferredtaxassetstaxdeferredexpensecompensationandbenefitssharebasedcompensationcost": 5002000,
    "deferredtaxassetsoperatingleaseliabilities": 1539000,
    "deferredtaxaseetsaccruedvacationandbonus": 846000,
    "deferredtaxassetsother": 1164000,
    "deferredtaxassetsgross": 76240000,
    "deferredtaxassetsnet": 1842000,
    "deferredtaxliabilitiesotherfinitelivedassets": 1534000,
    "deferredtaxliabilitiesprepaidexpenses": 243000,
    "deferredtaxliabilitiesdepreciationandamortization": 65000,
    "deferredincometaxliabilities": 1842000,
    "unrecognizedtaxbenefitsincreasesresultingfromcurrentperiodtaxpositions": 1730000,
    "contractualagreementcancelationnoticeperiod": "P30D",
    "landsubjecttogroundleases": 1577,
    "leasecommencementdate": "2016-05-31",
    "increaselandsubjecttoleases": 201,
    "lesseeoperatingleasetermofcontract": "P48D",
    "leaseexpirationdate1": "2021-12-31",
    "leaseandrentalexpense": 1200000,
    "othercommitmentsdescription": "In January 2021, the Company entered into an amendment to extend the lease, effective February 2021 with a termination date of January 2030, and increase the office and laboratory space",
    "operatingleasehandservingtosecureleaseobligation": 131000,
    "operatingleaseweightedaverageremainingleaseterm1": "P4Y7M6D",
    "operatingleaseweightedaveragediscountratepercent": 0.0475,
    "operatingleasepayments": 1201000,
    "lesseeoperatingleaseliabilitypaymentsduenexttwelvemonths": 1500000,
    "lesseeoperatingleaseliabilitypaymentsdueyeartwo": 1468000,
    "lesseeoperatingleaseliabilitypaymentsdueyearthree": 1435000,
    "lesseeoperatingleaseliabilitypaymentsdueyearfour": 941000,
    "lesseeoperatingleaseliabilitypaymentsdueyearfive": 764000,
    "lesseeoperatingleaseliabilitypaymentsdueafteryearfive": 590000,
    "lesseeoperatingleaseliabilitypaymentsdue": 6698000,
    "lesseeoperatingleaseliabilityundiscountedexcessamount": 640000,
    "operatingleaseliability": 6058000,
    "definedcontributionplanemployermatchingcontributionpercent": 0.05,
    "definedbenefitplancontributionsbyemployer": 675000,
    "definedcontributionplanmaximumannualcontributionsperemployeepercent": 1,
    "obligationtopayroyalties": "royalty equal to 1% of its net product sales on any product developed or owned by iTeos Therapeutics, Inc. or iTeos Belgium S.A., each year within 120 days following each year end.",
    "incomelossfromcontinuingoperations": -112642000,
    "commonstockothersharesoutstanding": 1692558
  },
  {
    "date": "2022-12-30",
    "symbol": "ITOS",
    "period": "FY",
    "documenttype": "10-K",
    "amendmentflag": "false",
    "documentperiodenddate": "December 31, 2022",
    "documentfiscalyearfocus": 2022,
    "documentfiscalperiodfocus": "FY",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "tradingsymbol": "ITOS",
    "entityregistrantname": "iTeos Therapeutics, Inc.",
    "entitycentralindexkey": 1808865,
    "currentfiscalyearenddate": "--12-31",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityinteractivedatacurrent": "Yes",
    "entityfilercategory": "Accelerated filer",
    "entitysmallbusiness": "false",
    "entityemerginggrowthcompany": "true",
    "entityextransitionperiod": "false",
    "entityincorporationstatecountrycode": "Delaware",
    "entityshellcompany": "true",
    "entityfilenumber": "001-39401",
    "entitytaxidentificationnumber": "84-3365066",
    "entityaddressaddressline1": "321 Arsenal St",
    "entityaddresscityortown": "Watertown",
    "entityaddressstateorprovince": "MA",
    "entityaddresspostalzipcode": 2472,
    "cityareacode": 339,
    "localphonenumber": "217 0161",
    "security12btitle": "Common stock, $0.001 par value per share",
    "securityexchangename": "Nasdaq Global Market",
    "icfrauditorattestationflag": "false",
    "auditorname": "Deloitte Bedrijfsrevisoren/Réviseurs d’Entreprises BV/SRL",
    "auditorlocation": "Zaventem, Belgium",
    "auditorfirmid": 1133,
    "cashandcashequivalentsatcarryingvalue": 284803000,
    "shortterminvestments": 328359000,
    "grantsreceivablecurrent": 996000,
    "incometaxreceivable": 1434000,
    "prepaidexpenseandotherassetscurrent": 12701000,
    "assetscurrent": 628298000,
    "propertyplantandequipmentnet": 2121000,
    "longterminvestments": 118225000,
    "researchanddevelopmenttaxcreditreceivablenoncurrent": 1128000,
    "restrictedcashnoncurrent": 235000,
    "operatingleaserightofuseasset": 4652000,
    "otherassetsnoncurrent": 332000,
    "assets": 754991000,
    "accountspayablecurrent": 7662000,
    "accountspayableandotheraccruedliabilitiescurrent": 4700000,
    "deferredincomecurrent": 1180000,
    "deferredrevenue": 12595000,
    "operatingleaseliabilitycurrent": 836000,
    "liabilitiescurrent": 42000000,
    "grantsrepayable": 6622000,
    "operatingleaseliabilitynoncurrent": 3837000,
    "unrecognizedtaxbenefits": 39200000,
    "liabilities": 91659000,
    "commonstockvalue": 36000,
    "additionalpaidincapital": 435665000,
    "accumulatedothercomprehensiveincomelossnetoftax": -9644000,
    "retainedearningsaccumulateddeficit": 237275000,
    "stockholdersequity": 237275000,
    "liabilitiesandstockholdersequity": 754991000,
    "debtsecuritiesavailableforsaleamortizedcostcurrent": 328405000,
    "debtsecuritiesavailableforsaleamortizedcostnoncurrent": 118330000,
    "preferredstockparorstatedvaluepershare": 0.001,
    "preferredstocksharesauthorized": "null",
    "commonstockparorstatedvaluepershare": 0.001,
    "commonstocksharesauthorized": "null",
    "commonstocksharesissued": "null",
    "commonstocksharesoutstanding": "null",
    "revenuefromcontractwithcustomerincludingassessedtax": 267600000.00000003,
    "revenues": 267630000,
    "researchanddevelopmentexpense": 97359000,
    "generalandadministrativeexpense": 43947000,
    "operatingexpenses": 141306000,
    "operatingincomeloss": 126324000,
    "grantincome": 1249000,
    "researchanddevelopmenttaxcredits": 1172000,
    "interestincomeother": 11361000,
    "othernonoperatingincomeexpense": 7788000,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": 148736000,
    "incometaxexpensebenefit": 1400000,
    "netincomeloss": 96652000,
    "netincomelossavailabletocommonstockholdersbasic": 96652000,
    "earningspersharebasic": 2.72,
    "earningspersharediluted": 2.56,
    "weightedaveragenumberofsharesoutstandingbasic": "null",
    "weightedaveragenumberofdilutedsharesoutstanding": "null",
    "othercomprehensiveincomelossforeigncurrencytransactionandtranslationadjustmentnetoftax": -8478000,
    "othercomprehensiveincomelossavailableforsalesecuritiesadjustmentnetoftax": -148000,
    "comprehensiveincomenetoftax": 88026000,
    "sharesoutstanding": "null",
    "adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalue": 21561000,
    "stockissuedduringperiodvaluestockoptionsexercised": 925000,
    "stockissuedduringperiodsharesstockoptionsexercised": 127478,
    "othercomprehensiveincomeforeigncurrencytransactionandtranslationgainlossarisingduringperiodnetoftax": -8478000,
    "debtsecuritiesavailableforsaleunrealizedgainloss": -148000,
    "profitloss": 96652000,
    "depreciationandamortization": 803000,
    "sharebasedcompensation": 21561000,
    "amortizationaccretionofavailableforsaledebtsecurities": -1728000,
    "changeinoperatingleaserightofuseassets": 10000,
    "increasedecreaseingrantsreceivable": 2751000,
    "increasedecreaseinresearchanddevelopmenttaxcreditreceivable": -1237000,
    "refundableincometaxes": 6107000,
    "increasedecreaseinprepaiddeferredexpenseandotherassets": -590000,
    "increasedecreaseinaccountspayable": 2761000,
    "increasedecreaseinaccruedliabilities": 3096000,
    "increasedecreaseincontractwithcustomerliability": 397000,
    "increasedecreaseindeferredrevenue": -267630000,
    "increasedecreaseinunrecognizedtaxbenefits": -22200000,
    "netcashprovidedbyusedinoperatingactivities": -111193000,
    "paymentstoacquireinvestments": 445004000,
    "paymentstoacquirepropertyplantandequipment": 938000,
    "paymentstoacquireotherproductiveassets": 120000,
    "netcashprovidedbyusedininvestingactivities": -446062000,
    "proceedsfromissuanceofcommonstock": 925000,
    "proceedsfromrepaymentsofrelatedpartydebt": 1059000,
    "netcashprovidedbyusedinfinancingactivities": 1984000,
    "effectofexchangerateoncashcashequivalentsrestrictedcashandrestrictedcashequivalentsincludingdisposalgroupanddiscontinuedoperations": -8526000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincludingexchangerateeffect": -563797000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalents": 285038000,
    "capitalexpenditureincludedinaccountspayable": 94000,
    "rightofuseassetobtainedinexchangeforoperatingleaseliability": 350000,
    "othercomprehensiveincomelossavailableforsalesecuritiesadjustmentbeforetax": 148000,
    "incometaxespaidnet": 22816000,
    "concentrationriskpercentage1": 0.99,
    "researchanddevelopmenttaxcreditspercentage": 0.135,
    "numberofoperatingsegments": 1,
    "propertyplantandequipmentusefullife": "6 years",
    "propertyplantandequipmentestimatedusefullives": "Shorter of useful life or term of  lease",
    "cashequivalentsatcarryingvalue": 92850000,
    "assetsfairvaluedisclosure": 552424000,
    "availableforsaledebtsecuritiesunrealizedlossdifference": 3000,
    "availableforsalesecuritiesdebtsecurities": 9600000,
    "proceedsfromsaleofavailableforsalesecuritiesdebt": 1800000,
    "availableforsaledebtsecuritiesamortizedcostbasis": 446735000,
    "availableforsaledebtsecuritiesaccumulatedgrossunrealizedgainbeforetax": 106000,
    "availableforsaledebtsecuritiesaccumulatedgrossunrealizedlossbeforetax": 257000,
    "availableforsalesecuritiesdebtmaturitieswithinoneyearamortizedcost": 328405000,
    "availableforsalesecuritiesdebtmaturitiesafteronethroughfiveyearsamortizedcost": 118330000,
    "availableforsalesecuritiesdebtmaturitieswithinoneyearfairvalue": 328359000,
    "availableforsalesecuritiesdebtmaturitiesafteronethroughfiveyearsfairvalue": 118225000,
    "propertyplantandequipmentgross": 5578000,
    "accumulateddepreciationdepletionandamortizationpropertyplantandequipment": 3457000,
    "accruedclinicaltrialcostscurrent": 13496000,
    "accruedpersonnelcostscurrent": 5635000,
    "accruedprofessionalfeescurrent": 64000,
    "otheraccruedliabilitiescurrent": 532000,
    "accruedliabilitiescurrent": 19727000,
    "upfrontpaymentreceived": 625000000,
    "maximumoptionfeesreceivablebasedonachievementofresearchmilestones": 45800000,
    "maximumadditionalreceivablebasedonachievementofresearchmilestones": 14500000,
    "additionalmilestonepaymentaccrued": 2000000,
    "contractwithcustomerliability": 12595000,
    "costsharecostsincurredforlicenseagreement": 30800000,
    "capitalizedcontractcostnet": 6800000,
    "costsrelatedtoglobaldevelopmentplan": 0.6,
    "paymentforlicenseagreementreimbursementofcostsincurred": 10200000,
    "relatedpartytransactionexpensesfromtransactionswithrelatedparty": 900000000,
    "contractwithcustomerliabilitydeductions": -267630000,
    "percentageofgrantreimburseofactualqualifyingexpenditures": 1,
    "researchanddevelopmentarrangementwithfederalgovernmentcostsincurrednet": 7400000,
    "royaltyaccrualsduetorevenuerecognized": 800000,
    "grantsreceivable": 4600000,
    "percentageofrepaymentamountreceivedundergrant": 0.3,
    "termofrepaymentamountreceivedundergrant": 2042,
    "percentageofroyaltyonrevenue": 0.0015,
    "deferredincomenoncurrent": 6600000,
    "proceedsreceivedfromgrants": 6261000,
    "capitalunitsauthorized": "null",
    "commonstockvotingrights": "Each share of common stock entitles the holders to one vote on all matters submitted to a vote of the Company’s stockholders.",
    "sharebasedcompensationarrangementbysharebasedpaymentawardexpirationperiod": 10,
    "sharebasedcompensationarrangementbysharebasedpaymentawardawardvestingrightspercentage": 0.25,
    "sharebasedcompensationarrangementbysharebasedpaymentawardawardvestingperiod1": "36 months",
    "sharebasedcompensationarrangementbysharebasedpaymentawardnumberofoptionsauthorized": "null",
    "commonstockcapitalsharesreservedforfutureissuance": 650191,
    "stockissuedduringperiodsharesemployeestockpurchaseplans": 17740,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodweightedaveragegrantdatefairvalue": 23.94,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisesinperiodtotalintrinsicvalue": 3200000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedinperiodfairvalue1": 20400000,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedsharebasedawardsotherthanoptions": 300000,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedperiodforrecognition1": 3.2,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": 0.5,
    "sharebasedcompensationarrangementbysharebasedpaymentawardpurchasepriceofcommonstockpercent": 0.85,
    "estimatedfairvalueofissuedshares": 6.5,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedpercentage": 0.25,
    "sharebasedcompensationarrangementbysharebasedpaymentawardpershareweightedaveragepriceofsharespurchased": 14.71,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsoutstandingweightedaverageremainingcontractualterms": "three years",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": "null",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": "null",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresinperiod": 39086,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingnumber": "null",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisablenumber": "null",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 18.5,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice": 32.8,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsforfeituresinperiodweightedaverageexerciseprice": 8,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodweightedaverageexerciseprice": 5.21,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingweightedaverageexerciseprice": 18.5,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageexerciseprice": 12.79,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": 7.1,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingweightedaverageremainingcontractualterm1": 7.1,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageremainingcontractualterm1": 6.3,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingintrinsicvalue": 40745000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingaggregateintrinsicvalue": 40745000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableintrinsicvalue1": 29670000,
    "allocatedsharebasedcompensationexpense": 21561000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrate": 0.0163,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrateminimum": 0.013700000000000002,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestratemaximum": 0.042300000000000004,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrate": 0.81,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrateminimum": 0.86,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityratemaximum": 0.9400000000000001,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionscommonstock": 17.3,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsnonvestednumber": 10000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiod": 10000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsnonvestedweightedaveragegrantdatefairvalue": 35.86,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodweightedaveragegrantdatefairvalue": 35.86,
    "incomelossfromcontinuingoperationsbeforeincometaxesdomestic": -72940000,
    "incomelossfromcontinuingoperationsbeforeincometaxesforeign": 44400000,
    "effectiveincometaxratecontinuingoperations": 0.35000000000000003,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.21,
    "valuationallowancedeferredtaxassetchangeinamount": 18800000,
    "deferredtaxassetsvaluationallowance": 45421000,
    "netoperatinglossavailabletooffsetratefortaxableincomelimitationundertcja": 0.8,
    "deferredtaxassetsoperatinglosscarryforwardsdomestic": 38400000,
    "operatinglosscarryforwardsexpirationyear": 2041,
    "dateexpiringdeminimisfederalfuturetaxliabilities": 2042,
    "dateexpiringstatetaxcreditavailabletoreducefuturetaxliabilities": 2037,
    "unrecognizedtaxbenefitsinterestonincometaxesaccrued": 2200000,
    "effectiveincometaxratereconciliationstateincometaxespercent": -0.022000000000000002,
    "effectiveincometaxratereconciliationforeignincometaxratedifferential": 0.052000000000000005,
    "effectiveincometaxratereconciliationrelatingtonontaxableincomeandnondeductibleexpense": 0.001,
    "effectiveincometaxratereconciliationtaxexemptincome": -0.334,
    "effectiveincometaxratereconciliationnetgiltiinclusionincome": 0.189,
    "effectiveincometaxrateunrecognizedtaxbenefits": 0.149,
    "effectiveincometaxratereconciliationotherreconcilingitemspercent": -0.03,
    "effectiveincometaxratereconciliationchangeinvaluationallowancepercent": 0.135,
    "currentfederalstateandlocaltaxexpensebenefit": 50750000,
    "currentforeigntaxexpensebenefit": 1334000,
    "deferredtaxassetsoperatinglosscarryforwards": 13359000,
    "deferredtaxassetstaxcreditcarryforwardsforeign": 12355000,
    "section174capitalizedresearchanddevelopmentexpenses": 14856000,
    "deferredtaxassetstaxdeferredexpensecompensationandbenefitssharebasedcompensationcost": 3860000,
    "deferredtaxassetsoperatingleaseliabilities": 1201000,
    "deferredtaxaseetsaccruedvacationandbonus": 552000,
    "deferredtaxassetsother": 932000,
    "deferredtaxassetsgross": 47115000,
    "deferredtaxassetsnet": 1694000,
    "deferredtaxliabilitiesotherfinitelivedassets": 1196000,
    "deferredtaxliabilitiesprepaidexpenses": 394000,
    "deferredtaxliabilitiesdepreciationandamortization": 104000,
    "deferredincometaxliabilities": 1694000,
    "unrecognizedtaxbenefitsincreasesresultingfromcurrentperiodtaxpositions": 22200000,
    "contractualagreementcancelationnoticeperiod": "60 days",
    "landsubjecttogroundleases": 9068,
    "leasecommencementdate": "2016-05-31",
    "increaselandsubjecttoleases": 453,
    "lesseeoperatingleasetermofcontract": "60 months",
    "leaseexpirationdate1": "2030-01-31",
    "leaseandrentalexpense": 900000,
    "othercommitmentsdescription": "In January 2021, the Company entered into an amendment to extend the lease, effective February 2021 with a termination date of January 2030, and increase the office and laboratory space",
    "operatingleasehandservingtosecureleaseobligation": 92000,
    "operatingleaseweightedaverageremainingleaseterm1": 5,
    "operatingleaseweightedaveragediscountratepercent": 0.0479,
    "operatingleasepayments": 860000,
    "lesseeoperatingleaseliabilitypaymentsduenexttwelvemonths": 1059000,
    "lesseeoperatingleaseliabilitypaymentsdueyeartwo": 1041000,
    "lesseeoperatingleaseliabilitypaymentsdueyearthree": 1010000,
    "lesseeoperatingleaseliabilitypaymentsdueyearfour": 980000,
    "lesseeoperatingleaseliabilitypaymentsdueyearfive": 489000,
    "lesseeoperatingleaseliabilitypaymentsdueafteryearfive": 770000,
    "lesseeoperatingleaseliabilitypaymentsdue": 5349000,
    "lesseeoperatingleaseliabilityundiscountedexcessamount": 676000,
    "operatingleaseliability": 4673000,
    "definedcontributionplanemployermatchingcontributionpercent": 0.05,
    "definedbenefitplancontributionsbyemployer": 278000,
    "definedcontributionplanmaximumannualcontributionsperemployeepercent": 1,
    "obligationtopayroyalties": "royalty equal to 1% of its net product sales on any product developed or owned by iTeos Therapeutics, Inc. or iTeos Belgium S.A., each year within 120 days following each year end.",
    "incomelossfromcontinuingoperations": 96652000,
    "incrementalcommonsharesattributabletosharebasedpaymentarrangements": "null"
  },
  {
    "date": "2021-12-30",
    "symbol": "ITOS",
    "period": "FY",
    "documenttype": "10-K",
    "amendmentflag": "false",
    "documentperiodenddate": "December 31, 2021",
    "documentfiscalyearfocus": 2021,
    "documentfiscalperiodfocus": "FY",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "tradingsymbol": "ITOS",
    "entityregistrantname": "iTeos Therapeutics, Inc.",
    "entitycentralindexkey": 1808865,
    "currentfiscalyearenddate": "--12-31",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityinteractivedatacurrent": "Yes",
    "entityfilercategory": "Non-accelerated filer",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "true",
    "entityextransitionperiod": "false",
    "entityincorporationstatecountrycode": "Delaware",
    "entityshellcompany": "true",
    "entityfilenumber": "001-39401",
    "entitytaxidentificationnumber": "84-3365066",
    "entityaddressaddressline1": "321 Arsenal St",
    "entityaddresscityortown": "Watertown",
    "entityaddressstateorprovince": "MA",
    "entityaddresspostalzipcode": 2472,
    "cityareacode": 339,
    "localphonenumber": "217 0161",
    "security12btitle": "Common stock, $0.001 par value per share",
    "securityexchangename": "Nasdaq Global Market",
    "icfrauditorattestationflag": "false",
    "auditorname": "Deloitte Bedrijfsrevisoren/Réviseurs d’Entreprises BV/SRL",
    "auditorlocation": "Zaventem, Belgium",
    "auditorfirmid": 1133,
    "cashandcashequivalentsatcarryingvalue": 848537000,
    "grantsreceivablecurrent": 1093000,
    "researchanddevelopmenttaxcreditreceivablecurrent": 524000,
    "incometaxreceivable": 7544000,
    "prepaidexpenseandotherassetscurrent": 14086000,
    "assetscurrent": 874713000,
    "propertyplantandequipmentnet": 2072000,
    "researchanddevelopmenttaxcreditreceivablenoncurrent": 2004000,
    "restrictedcashnoncurrent": 298000,
    "operatingleaserightofuseasset": 5329000,
    "otherassetsnoncurrent": 296000,
    "assets": 884712000,
    "accountspayablecurrent": 5145000,
    "accountspayableandotheraccruedliabilitiescurrent": 17157000,
    "deferredincomecurrent": 827000,
    "deferredrevenue": 280225000,
    "operatingleaseliabilitycurrent": 770000,
    "liabilitiescurrent": 304124000,
    "grantsrepayable": 6164000,
    "operatingleaseliabilitynoncurrent": 4571000,
    "unrecognizedtaxbenefits": 17000000,
    "otherliabilitiesnoncurrent": 33000,
    "liabilities": 331892000,
    "commonstockvalue": 35000,
    "additionalpaidincapital": 413180000,
    "accumulatedothercomprehensiveincomelossnetoftax": -1018000,
    "retainedearningsaccumulateddeficit": 140623000,
    "stockholdersequity": 140623000,
    "liabilitiesandstockholdersequity": 884712000,
    "preferredstockparorstatedvaluepershare": 0.001,
    "preferredstocksharesauthorized": "null",
    "commonstockparorstatedvaluepershare": 0.001,
    "commonstocksharesauthorized": "null",
    "commonstocksharesissued": "null",
    "commonstocksharesoutstanding": "null",
    "revenuefromcontractwithcustomerincludingassessedtax": 344800000,
    "revenues": 344775000,
    "researchanddevelopmentexpense": 59369000,
    "generalandadministrativeexpense": 40505000,
    "operatingexpenses": 99874000,
    "operatingincomeloss": 244901000,
    "grantincome": 4782000,
    "othernonoperatingincomeexpense": 1382000,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": 256464000,
    "incometaxexpensebenefit": 400000,
    "netincomeloss": 214521000,
    "netincomelossavailabletocommonstockholdersbasic": 214521000,
    "earningspersharebasic": 6.1,
    "earningspersharediluted": 5.68,
    "weightedaveragenumberofsharesoutstandingbasic": "null",
    "weightedaveragenumberofdilutedsharesoutstanding": "null",
    "othercomprehensiveincomelossforeigncurrencytransactionandtranslationadjustmentnetoftax": -1635000,
    "comprehensiveincomenetoftax": 212886000,
    "sharesoutstanding": "null",
    "adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalue": 13794000,
    "stockissuedduringperiodvaluestockoptionsexercised": 2943000,
    "stockissuedduringperiodsharesstockoptionsexercised": 421947,
    "othercomprehensiveincomeforeigncurrencytransactionandtranslationgainlossarisingduringperiodnetoftax": -1635000,
    "profitloss": 214521000,
    "depreciationandamortization": 603000,
    "sharebasedcompensation": 13794000,
    "changeinoperatingleaserightofuseassets": 12000,
    "increasedecreaseingrantsreceivable": -4071000,
    "increasedecreaseinresearchanddevelopmenttaxcreditreceivable": 727000,
    "refundableincometaxes": -7544000,
    "increasedecreaseinprepaiddeferredexpenseandotherassets": -11789000,
    "increasedecreaseinaccountspayable": 2280000,
    "increasedecreaseinaccruedliabilities": 9959000,
    "increasedecreaseincontractwithcustomerliability": 3480000,
    "increasedecreaseindeferredrevenue": 281128000,
    "increasedecreaseinunrecognizedtaxbenefits": 17000000,
    "netcashprovidedbyusedinoperatingactivities": 513140000,
    "paymentstoacquirepropertyplantandequipment": 1181000,
    "paymentstoacquireotherproductiveassets": 61000,
    "netcashprovidedbyusedininvestingactivities": -1242000,
    "proceedsfromissuanceofcommonstock": 2943000,
    "proceedsfromrepaymentsofrelatedpartydebt": 716000,
    "netcashprovidedbyusedinfinancingactivities": 3659000,
    "effectofexchangerateoncashandcashequivalents": -3176000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincludingexchangerateeffect": 512381000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalents": 848835000,
    "capitalexpenditureincludedinaccountspayable": 175000,
    "rightofuseassetobtainedinexchangeforoperatingleaseliability": 5877000,
    "incometaxespaidnet": 32019000,
    "convertiblepreferredstocksharesissueduponconversion": "null",
    "researchanddevelopmenttaxcreditspercentage": 0.135,
    "numberofoperatingsegments": 1,
    "propertyplantandequipmentusefullife": "6 years",
    "propertyplantandequipmentestimatedusefullives": "Shorter of useful life or term of  lease",
    "cashequivalentsatcarryingvalue": 797448000,
    "financialinstrumentsownedatfairvalue": 797448000,
    "propertyplantandequipmentgross": 5043000,
    "accumulateddepreciationdepletionandamortizationpropertyplantandequipment": 2971000,
    "accruedclinicaltrialcostscurrent": 12991000,
    "accruedpersonnelcostscurrent": 3884000,
    "accruedprofessionalfeescurrent": 25000,
    "otheraccruedliabilitiescurrent": 257000,
    "accruedliabilitiescurrent": 17157000,
    "upfrontpaymentreceived": 625000000,
    "maximumoptionfeesreceivablebasedonachievementofresearchmilestones": 45800000,
    "maximumadditionalreceivablebasedonachievementofresearchmilestones": 14500000,
    "contractwithcustomerliability": 280225000,
    "costsharecostsincurredforlicenseagreement": 11500000,
    "capitalizedcontractcostnet": 6800000,
    "costsrelatedtoglobaldevelopmentplan": 0.6,
    "paymentforlicenseagreementreimbursementofcostsincurred": 4800000,
    "duetorelatedpartiescurrentandnoncurrent": 3000000,
    "relatedpartytransactionexpensesfromtransactionswithrelatedparty": 900000000,
    "contractwithcustomerliabilityadditions": 625000000,
    "contractwithcustomerliabilitydeductions": -344775000,
    "percentageofgrantreimburseofactualqualifyingexpenditures": 1,
    "researchanddevelopmentarrangementwithfederalgovernmentcostsincurrednet": 1500000,
    "royaltyaccrualsduetorevenuerecognized": 900000,
    "percentageofrepaymentamountreceivedundergrant": 0.3,
    "termofrepaymentamountreceivedundergrant": 2042,
    "percentageofroyaltyonrevenue": 0.0015,
    "deferredincomenoncurrent": 6164000,
    "proceedsreceivedfromgrants": 3167000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardexpirationperiod": 10,
    "sharebasedcompensationarrangementbysharebasedpaymentawardawardvestingrightspercentage": 0.25,
    "sharebasedcompensationarrangementbysharebasedpaymentawardawardvestingperiod1": "36 months",
    "sharebasedcompensationarrangementbysharebasedpaymentawardnumberofoptionsauthorized": "null",
    "commonstockcapitalsharesreservedforfutureissuance": 667931,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodweightedaveragegrantdatefairvalue": 27.46,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisesinperiodtotalintrinsicvalue": 11000000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedinperiodfairvalue1": 10700000,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedsharebasedawardsotherthanoptions": 38100000,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedperiodforrecognition1": 2.8,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": 6,
    "cumulativeincreaseincommonstocksharesreserveforissuance": "null",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": "null",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": "null",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresinperiod": 28031,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingnumber": "null",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisablenumber": "null",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 14.35,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice": 33.39,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsforfeituresinperiodweightedaverageexerciseprice": 27.02,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodweightedaverageexerciseprice": 6.98,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingweightedaverageexerciseprice": 14.35,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageexerciseprice": 8.06,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": 7.7,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingweightedaverageremainingcontractualterm1": 7.7,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageremainingcontractualterm1": 6.2,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingintrinsicvalue": 167709,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingaggregateintrinsicvalue": 167709,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableintrinsicvalue1": 78747,
    "allocatedsharebasedcompensationexpense": 13794000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrateminimum": 0.0042,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestratemaximum": 0.012700000000000001,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrateminimum": 0.92,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityratemaximum": 1,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionscommonstock": 46.68,
    "incomelossfromcontinuingoperationsbeforeincometaxesdomestic": -47242000,
    "incomelossfromcontinuingoperationsbeforeincometaxesforeign": 56300000,
    "effectiveincometaxratecontinuingoperations": 0.16399999999999998,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.21,
    "valuationallowancedeferredtaxassetchangeinamount": 5400000,
    "deferredtaxassetsvaluationallowance": 26647000,
    "netoperatinglossavailabletooffsetratefortaxableincomelimitationundertcja": 0.8,
    "operatinglosscarryforwards": 100000,
    "deferredtaxassetsoperatinglosscarryforwardsdomestic": 52000000,
    "operatinglosscarryforwardsexpirationyear": 2041,
    "dateexpiringdeminimisfederalfuturetaxliabilities": 2041,
    "dateexpiringstatetaxcreditavailabletoreducefuturetaxliabilities": 2036,
    "effectiveincometaxratereconciliationstateincometaxespercent": -0.005,
    "effectiveincometaxratereconciliationforeignincometaxratedifferential": 0.047,
    "effectiveincometaxratereconciliationrelatingtonontaxableincomeandnondeductibleexpense": 0.001,
    "effectiveincometaxratereconciliationtaxexemptincome": -0.282,
    "effectiveincometaxratereconciliationnetgiltiinclusionincome": 0.152,
    "effectiveincometaxrateunrecognizedtaxbenefits": 0.066,
    "effectiveincometaxratereconciliationotherreconcilingitemspercent": -0.011000000000000001,
    "effectiveincometaxratereconciliationchangeinvaluationallowancepercent": -0.013999999999999999,
    "currentfederalstateandlocaltaxexpensebenefit": 41535000,
    "currentforeigntaxexpensebenefit": 408000,
    "deferredtaxassetsoperatinglosscarryforwards": 17097000,
    "deferredtaxassetstaxcreditcarryforwardsforeign": 7884000,
    "deferredtaxassetstaxdeferredexpensecompensationandbenefitssharebasedcompensationcost": 1784000,
    "deferredtaxassetsoperatingleaseliabilities": 1374000,
    "deferredtaxassetsaccruedbonus": 390000,
    "deferredtaxassetsother": 17000,
    "deferredtaxassetsgross": 28546000,
    "deferredtaxassetsnet": 1899,
    "deferredtaxliabilitiesotherfinitelivedassets": 1371000,
    "deferredtaxliabilitiesprepaidexpenses": 497000,
    "deferredtaxliabilitiesdepreciationandamortization": -31000,
    "deferredincometaxliabilities": 1899000,
    "unrecognizedtaxbenefitsincreasesresultingfromcurrentperiodtaxpositions": 17000000,
    "contractualagreementcancelationnoticeperiod": "60 days",
    "landsubjecttogroundleases": 9068,
    "leasecommencementdate": "2021-11-30",
    "increaselandsubjecttoleases": 453,
    "lesseeoperatingleasetermofcontract": "60 months",
    "leaseexpirationdate1": "2027-02-28",
    "leaseandrentalexpense": 700000,
    "othercommitmentsdescription": "In January 2021, the Company entered into an amendment to extend the lease, effective February 2021 with a termination date of January 2030, and increase the office and laboratory space",
    "operatingleasehandservingtosecureleaseobligation": 99000,
    "operatingleaseweightedaverageremainingleaseterm1": 5.9,
    "operatingleaseweightedaveragediscountratepercent": 0.047599999999999996,
    "operatingleasepayments": 767000,
    "lesseeoperatingleaseliabilitypaymentsduenexttwelvemonths": 920000,
    "lesseeoperatingleaseliabilitypaymentsdueyeartwo": 1001000,
    "lesseeoperatingleaseliabilitypaymentsdueyearthree": 997000,
    "lesseeoperatingleaseliabilitypaymentsdueyearfour": 990000,
    "lesseeoperatingleaseliabilitypaymentsdueyearfive": 917000,
    "lesseeoperatingleaseliabilitypaymentsdueafteryearfive": 1418000,
    "lesseeoperatingleaseliabilitypaymentsdue": 6243000,
    "lesseeoperatingleaseliabilityundiscountedexcessamount": 902000,
    "operatingleaseliability": 5341000,
    "definedcontributionplanemployermatchingcontributionpercent": 0.05,
    "definedbenefitplancontributionsbyemployer": 82000000,
    "definedcontributionplanmaximumannualcontributionsperemployeepercent": 1,
    "obligationtopayroyalties": "royalty equal to 1% of its net product sales on any product developed or owned by iTeos Therapeutics, Inc. or iTeos Belgium S.A., each year within 120 days following each year end.",
    "incomelossfromcontinuingoperations": 214521000,
    "incrementalcommonsharesattributabletosharebasedpaymentarrangements": "null"
  },
  {
    "date": "2020-12-30",
    "symbol": "ITOS",
    "period": "FY",
    "documenttype": "10-K",
    "amendmentflag": "false",
    "documentperiodenddate": "2020-12-31",
    "documentfiscalyearfocus": 2020,
    "documentfiscalperiodfocus": "FY",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "tradingsymbol": "ITOS",
    "entityregistrantname": "iTeos Therapeutics, Inc.",
    "entitycentralindexkey": 1808865,
    "currentfiscalyearenddate": "--12-31",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityinteractivedatacurrent": "Yes",
    "entityfilercategory": "Non-accelerated Filer",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "true",
    "entityextransitionperiod": "false",
    "entityincorporationstatecountrycode": "DE",
    "entityshellcompany": "false",
    "entityfilenumber": "001-39401",
    "entitytaxidentificationnumber": "84-3365066",
    "entityaddressaddressline1": "139 Main Street",
    "entityaddresscityortown": "Cambridge",
    "entityaddressstateorprovince": "MA",
    "entityaddresspostalzipcode": 2142,
    "cityareacode": 339,
    "localphonenumber": "217 0161",
    "security12btitle": "Common stock, $0.001 par value per share",
    "securityexchangename": "NASDAQ",
    "icfrauditorattestationflag": "false",
    "cashandcashequivalentsatcarryingvalue": 336326000,
    "grantsreceivablecurrent": 133000,
    "researchanddevelopmenttaxcreditreceivablecurrent": 192000,
    "prepaidexpenseandotherassetscurrent": 2893000,
    "assetscurrent": 339544000,
    "propertyplantandequipmentnet": 1352000,
    "researchanddevelopmenttaxcreditreceivablenoncurrent": 3286000,
    "restrictedcashnoncurrent": 128000,
    "otherassetsnoncurrent": 248000,
    "assets": 344558000,
    "accountspayablecurrent": 3026000,
    "accountspayableandotheraccruedliabilitiescurrent": 7486000,
    "deferredincomecurrent": 4486000,
    "liabilitiescurrent": 14998000,
    "grantsrepayable": 5883000,
    "otherliabilitiesnoncurrent": 480000,
    "liabilities": 21361000,
    "commonstockvalue": 35000,
    "additionalpaidincapital": 396443000,
    "accumulatedothercomprehensiveincomelossnetoftax": 617000,
    "retainedearningsaccumulateddeficit": 73900000,
    "stockholdersequity": -73898000,
    "liabilitiesandstockholdersequity": 344558000,
    "preferredstockparorstatedvaluepershare": 0.001,
    "preferredstocksharesauthorized": 10000000,
    "commonstockparorstatedvaluepershare": 0.001,
    "commonstocksharesauthorized": 150000000,
    "commonstocksharesissued": 35044758,
    "commonstocksharesoutstanding": 35044758,
    "researchanddevelopmentexpense": 29900000,
    "generalandadministrativeexpense": 15340000,
    "operatingexpenses": 45240000,
    "operatingincomeloss": -45240000,
    "grantincome": 444000,
    "researchanddevelopmenttaxcredits": 286000,
    "fairvalueadjustmentforpreferredstocktrancherightsandantidilutionwarrantliabilities": 1265000,
    "othernonoperatingincomeexpense": -48000,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": -38090000,
    "incometaxexpensebenefit": 57000,
    "netincomeloss": 38000000,
    "dividendspreferredstock": 249000,
    "preferredstockaccretionofredemptiondiscount": 5120000,
    "netincomelossavailabletocommonstockholdersbasic": -43402000,
    "earningspersharebasicanddiluted": -2.88,
    "weightedaveragenumberofshareoutstandingbasicanddiluted": 15080266,
    "othercomprehensiveincomelossforeigncurrencytransactionandtranslationadjustmentnetoftax": 841000,
    "comprehensiveincomenetoftax": -37192000,
    "sharesoutstanding": 35044758,
    "temporaryequitystockissuedduringperiodvaluenewissues": 125026000,
    "temporaryequitystockissuedduringperiodsharesnewissues": 44453477,
    "settlementofpreferredstocktrancheright": 4135000,
    "temporaryequityaccretiontoredemptionvalueincreasedecrease": 5120000,
    "stockissuedduringperiodvalueconversionofconvertiblesecurities": 181903000,
    "stockissuedduringperiodsharesconversionofconvertiblesecurities": 22460076,
    "stockissuedduringperiodvaluenewissues": 210612000,
    "stockissuedduringperiodsharesnewissues": 12091675,
    "stockissuedduringperiodvaluestockoptionsexercised": 655000,
    "stockissuedduringperiodsharesstockoptionsexercised": 236459,
    "adjustmentstoadditionalpaidincapitalsharebasedcompensationrequisiteserviceperiodrecognitionvalue": 4292000,
    "othercomprehensiveincomeforeigncurrencytransactionandtranslationgainlossarisingduringperiodnetoftax": 841000,
    "paymentsofstockissuancecosts": 332000,
    "profitloss": -38033000,
    "depreciationandamortization": 535000,
    "sharebasedcompensation": 4292000,
    "deferredrentadjustments": 35000,
    "increasedecreaseingrantsreceivable": 5175000,
    "increasedecreaseinresearchanddevelopmenttaxcreditreceivable": 142000,
    "increasedecreaseinprepaiddeferredexpenseandotherassets": 1927000,
    "increasedecreaseinaccountspayable": 1677000,
    "increasedecreaseinaccruedliabilities": 2759000,
    "increasedecreaseincontractwithcustomerliability": 1788000,
    "netcashprovidedbyusedinoperatingactivities": -25176000,
    "paymentstoacquirepropertyplantandequipment": 356000,
    "paymentstoacquireotherproductiveassets": 21000,
    "netcashprovidedbyusedininvestingactivities": -377000,
    "proceedsfromissuanceinitialpublicoffering": 213660000,
    "paymentsforinitialpublicofferingcosts": 3048000,
    "proceedsfromissuanceofpreferredstockandpreferencestock": 125358000,
    "proceedsfromissuanceofcommonstock": 655000,
    "proceedsfromrepaymentsofrelatedpartydebt": 4046000,
    "netcashprovidedbyusedinfinancingactivities": 340339000,
    "effectofexchangerateoncashandcashequivalents": 1678000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincludingexchangerateeffect": 316464000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalents": 336454000,
    "conversionofstockamountconverted1": 181903000,
    "incometaxespaidnet": 108000,
    "convertiblepreferredstocksharesissueduponconversion": 22460076,
    "researchanddevelopmenttaxcreditspercentage": 0.135,
    "numberofoperatingsegments": 1,
    "propertyplantandequipmentusefullife": "P6Y",
    "propertyplantandequipmentestimatedusefullives": "Shorter of useful life or term of  lease",
    "cashequivalentsatcarryingvalue": 314636000,
    "financialinstrumentsownedatfairvalue": 314636000,
    "seriesbantidilutionwarrantprovidedtoinvestors": 1,
    "classofwarrantorrightexercisepriceofwarrantsorrights1": 0.01,
    "fairvaluemeasurementwithunobservableinputsreconciliationrecurringbasisliabilityperiodincreasedecrease": 1265000,
    "fairvaluemeasurementwithunobservableinputsreconciliationrecurringbasisliabilitysettlements": 4135000,
    "fairvaluemeasurementwithunobservableinputsreconciliationrecurringbasisliabilitygainlossincludedinearnings": 1265000,
    "propertyplantandequipmentgross": 4014000,
    "accumulateddepreciationdepletionandamortizationpropertyplantandequipment": 2662000,
    "accruedclinicaltrialcostscurrent": 4012000,
    "accruedpersonnelcostscurrent": 3208000,
    "accruedprofessionalfeescurrent": 37000,
    "otheraccruedliabilitiescurrent": 229000,
    "accruedliabilitiescurrent": 7486000,
    "maximumoptionfeesreceivablebasedonachievementofresearchmilestonesperprogram": 400000,
    "maximumoptionfeesreceivablebasedonachievementofresearchmilestones": 42800000,
    "maximumadditionalreceivablebasedonachievementofresearchmilestones": 13500000,
    "revenuefromcontractwithcustomerincludingassessedtax": 3400000,
    "percentageofgrantreimburseofactualqualifyingexpenditures": 1,
    "researchanddevelopmentarrangementwithfederalgovernmentcostsincurrednet": 5600000,
    "researchanddevelopmentarrangementwithfederalgovernmentcustomerfundingtooffsetcostsincurred": 1300000,
    "percentageofrepaymentamountreceivedundergrant": 0.3,
    "termofrepaymentamountreceivedundergrant": 2041,
    "percentageofroyaltyonrevenue": 0.0012,
    "deferredincomenoncurrent": 5883000,
    "proceedsreceivedfromgrants": 17053000,
    "stockoptionsissuedandoutstanding": 4552396,
    "sharesavailableforissuanceunderstockoptionplan": 3039222,
    "commonstockcapitalsharesreservedforfutureissuance": 7591618,
    "sharebasedcompensationarrangementbysharebasedpaymentawardexpirationperiod": "P10Y",
    "sharebasedcompensationarrangementbysharebasedpaymentawardawardvestingrightspercentage": 0.25,
    "sharebasedcompensationarrangementbysharebasedpaymentawardawardvestingperiod1": "P36M",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodweightedaveragegrantdatefairvalue": 7.75,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisesinperiodtotalintrinsicvalue": 3100000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedinperiodfairvalue1": 800000,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedsharebasedawardsotherthanoptions": 23600000,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedperiodforrecognition1": "P3Y4M24D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 4552396,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": 3504715,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresinperiod": 102863,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingnumber": 4552396,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisablenumber": 861388,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 9.13,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice": 10.43,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsforfeituresinperiodweightedaverageexerciseprice": 7.18,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodweightedaverageexerciseprice": 2.77,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingweightedaverageexerciseprice": 9.13,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageexerciseprice": 4.93,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": "P8Y2M12D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingweightedaverageremainingcontractualterm1": "P8Y2M12D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageremainingcontractualterm1": "P5Y",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingintrinsicvalue": 112412000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingaggregateintrinsicvalue": 112412000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableintrinsicvalue1": 24889000,
    "allocatedsharebasedcompensationexpense": 4292000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrateminimum": 0.0036,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestratemaximum": 0.0135,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": "P6Y",
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrateminimum": 0.9,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityratemaximum": 1.02,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionscommonstock": 33.12,
    "incomelossfromcontinuingoperationsbeforeincometaxesdomestic": -31184000,
    "incomelossfromcontinuingoperationsbeforeincometaxesforeign": 69200000,
    "effectiveincometaxratecontinuingoperations": 0.002,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.21,
    "deferredtaxassetsvaluationallowance": 32029000,
    "netincreasedecreaseindeferredtaxassetsvaluationallowance": 10300000,
    "netoperatinglosscarryforwardsavailabletooffsetfutureincometaxliabilities": 29200000,
    "netoperatinglosscarryforwardsdeductibleatmaximumrateofcorporationstaxableincome": 0.8,
    "netoperatinglossavailabletooffsetratefortaxableincomelimitationundertcja": 0.8,
    "operatinglosscarryforwardslimitationsonuse": 0.1,
    "operatinglosscarryforwards": 29000000,
    "dateexpiringnetoperatinglosscarryforwardsavailabletooffsetfutureincometaxliabilities": 2040,
    "dateexpiringdeminimisfederalfuturetaxliabilities": 2040,
    "dateexpiringstatetaxcreditavailabletoreducefuturetaxliabilities": 2025,
    "effectiveincometaxratereconciliationstateincometaxespercent": 0.048,
    "effectiveincometaxratereconciliationforeignincometaxratedifferential": 0.008,
    "effectiveincometaxratereconciliationrelatingtonontaxableincomeandnondeductibleexpense": 0.034,
    "effectiveincometaxratereconciliationlocalincometaxespercent": -0.086,
    "effectiveincometaxratereconciliationotherreconcilingitemspercent": 0.009,
    "effectiveincometaxratereconciliationchangeinvaluationallowancepercent": -0.221,
    "currentfederalstateandlocaltaxexpensebenefit": -60000,
    "currentforeigntaxexpensebenefit": 3000,
    "deferredtaxassetsoperatinglosscarryforwards": 25206000,
    "deferredtaxassetstaxcreditcarryforwardsresearch": 6219000,
    "deferredtaxassetstaxdeferredexpensecompensationandbenefitssharebasedcompensationcost": 758000,
    "deferredtaxassetsother": 313000,
    "deferredtaxassetsgross": 32496000,
    "deferredtaxassetsnet": 467000,
    "deferredtaxliabilitiesprepaidexpenses": 445000,
    "deferredtaxliabilitiesdepreciationandamortization": 22000,
    "deferredincometaxliabilities": 467000,
    "contractualagreementcancelationnoticeperiod": "P60D",
    "lesseeoperatingleasetermofcontract": "P4Y",
    "leaseexpirationdate1": "2022-05-31",
    "leaseandrentalexpense": 600000,
    "othercommitmentsdescription": "In January 2021, the Company entered into an agreement to extend its office lease in Belgium effective February 1, 2021 through January 2030 and include additional space",
    "operatingleasehandservingtosecureleaseobligation": 71000000,
    "lesseeoperatingleaseliabilitypaymentsduenexttwelvemonths": 667000,
    "lesseeoperatingleaseliabilitypaymentsdueyeartwo": 504000,
    "lesseeoperatingleaseliabilitypaymentsdueyearthree": 385000,
    "lesseeoperatingleaseliabilitypaymentsdueyearfour": 349000,
    "lesseeoperatingleaseliabilitypaymentsdueyearfive": 318000,
    "lesseeoperatingleaseliabilitypaymentsdueafteryearfive": 1369000,
    "lesseeoperatingleaseliabilitypaymentsdue": 3592000,
    "definedcontributionplanemployermatchingcontributionpercent": 0.05,
    "definedbenefitplancontributionsbyemployer": 28000000,
    "definedcontributionplanmaximumannualcontributionsperemployeepercent": 1,
    "obligationtopayroyalties": "royalty equal to 1% percent of its net product sales on any product developed or owned by iTeos Therapeutics, Inc. or iTeos Belgium SA, each year within 120 days following each year end.",
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 4552396
  }
]